Trial Condition(s):

Macular degeneration

Eylea Post Marketing Surveillance(PMS)

Bayer Identifier:

16469

ClinicalTrials.gov Identifier:

NCT01783925

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The objective of this PMS is to gain information about safety and efficacy in real practice as a regulatory commitment required by MFDS

Inclusion Criteria
- Patients determined to start EYLEA treatment 
 - Patients who agree and sign informed consent
 - Patients who receive EYLEA treatment for the first time
 - Patients who meet one of the following 
 -- Patients diagnosed by physician as having neovascular (wet) age-related macular degeneration wAMD
 -- Patients diagnosed by physician as having visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO)
 -- Patients diagnosed as having visual impairment due to diabetic macular edema (DME)
 -- Patients diagnosed as having visual impairment due to myopic choroidal neovascularization (mCNV)
Exclusion Criteria
- Patients who have received anti-VEGF therapy within 90 days       
 - Patients who are contraindicated based on the approved product label
 -- Ocular or periocular infection
 -- Active severe intraocular inflammation
 -- Known hypersensitivity to any ingredient of this drug

Trial Summary

Enrollment Goal
3206
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Many Locations

Many Locations, South Korea

Status
Completed
 

Trial Design